academic degree
2000.09-2005.07
Doctor of Pharmacology, Peking Union Medical College.
1993.09- 1997.07
Hunan University of Traditional Chinese Medicine, Bachelor of Pharmacy.
Business experience
July 2005 to present
Tsinghua University, Biochemical Pharmacology, Postdoctoral Research.
1997.09-2000.07
Teaching assistant of pharmacology in Yiyang Health School, Hunan Province.
Research direction:
Mainly engaged in endocrine, immune and cardiovascular pharmacological research. Establish a suitable or new whole animal and in vitro screening platform by biological means, and screen the activities of related biological and natural compounds, explore their mechanism of action and develop new products.
Research results: More than 0 pharmacological papers 10 were published in domestic and foreign magazines, among which 9 were included in SCI and 6 were the first authors.
Research areas:
Molecular pharmacology and innovative drug research. Now I am mainly engaged in making animal models such as diabetes, hyperlipidemia and obesity. Using pharmacological thinking and relying on technical platforms such as molecular and cell biology, we explore the pathogenesis of these diseases and find effective targets and innovative drugs that can effectively prevent and treat this type of diseases and complications.
Scientific research projects undertaken and participated in:
At present, he is in charge of scientific research projects 1 item such as National Natural Science Foundation, University Doctoral Program Fund-New Teachers, Guangdong Natural Science Fund, China Postdoctoral Science Fund, Shenzhen Nanshan District Science and Technology Fund and Academy of Sciences Seed Fund. As an important technical backbone, he participated in many projects such as the National Natural Science Foundation, the National Natural Science Foundation-China-Canada Cooperation, and the national "Eleventh Five-Year Plan" and "Twelfth Five-Year Plan" major special new drug creation.
[1] The second batch of "major new drug creation" major scientific and technological projects in the Twelfth Five-Year Plan: research on BLP, a new drug for glucose and lipid metabolism (approval number: 2012zx09103-201-041). Principal of the main pharmacodynamics student project, 6.5438+0.48 million.
[2] The second batch of "major new drug creation" in the Twelfth Five-Year Plan: research on small nucleic acid drugs for inhibiting tumor angiogenesis and tumor metastasis (authorization number: 2012zx09102301-0/9). Deputy head of major pharmacodynamics projects.
[3] National Natural Science Foundation of China (GrantNo.: 8 1072680).TZDs "Anchored" in endogenous miR- 18 1a regulates inflammatory signaling pathway and islet protection mechanism of monocyte TLRs under high glucose, 2011A.
[4] Doctoral Program Fund of Ministry of Education-New Teachers (GrantNo.: 2010002120017). MiR- 18 1a anchored in TLRs signaling pathway mediates the new mechanism of high glucose-induced monocyte inflammation, 2011.1-2013.12, presided over.
[5] Guangdong Natural Science Foundation (GrantNo.:1018057020002). The new role and mechanism of miR- 18 1a anchored in TLRs signal pathway in regulating hyperglycemia inflammation, 20/.
[6] Shenzhen Nanshan District Science and Technology Plan Project (Approval No.2008028). Microbes, Obesity and Effective Chinese Medicine Research, 2009-20 10, presided over, 65,438+10,000.
China Postdoctoral Science Foundation (GrantNo.: 20060390460). Molecular Mechanism of Obesity Susceptibility and Resistance of Mouse Abdominal Adipocytes Proliferation and Differentiation, July 2005-June 2007, presided over, 30000.
[8] Research Seed Fund of Shenzhen Graduate School of Tsinghua University in 2008. Study on the relationship between type 2 diabetes and inflammation and the development of Chinese herbal medicine preventive products, 2008.438+0-2009.438+02, presided over, 50,000 yuan.
[9] National Natural Science Foundation of China (GrantNo.: 30572340). Evaluating the comprehensive effects of pomegranate leaves total tannins and its main active components on adipocytes by mathematical model, 2006.438+0-2008.02, participated in.
National Natural Science Foundation of China (GrantNo.: 30871428). Study on the Mechanism of MicroRNA Regulating Adipocyte Differentiation, 2009+0-20438+0438+0.438+02, participated in.
National Natural Science Foundation of China (GrantNo.: 3091120492). Regulation of MicroRNA-626 by 3' untranslated fragment of Versican, 2010/-20/kloc-.
Major scientific and technological project "Creation of Major New Drugs" in the 11th Five-Year Plan (GrantNo.: 2009ZX09 103-7 15). Research on small nucleic acid drugs for inhibiting tumor angiogenesis and tumor metastasis, 2009+0-20438+00-638+02, participation.
Papers and patents:
At present, there are 35 articles published at home and abroad, including 25 SCI papers (first author 15, second author 5); In addition, the first author or correspondent has published 1 Ei document and 4 domestic core articles; Participate in the preparation of pharmacological chapters of about 20 thousand words in related books such as Frontier of Pharmacy and Flora of Chinese Medicinal Plants; Apply for more than 3 patents.